Want to see ORMP full AI Analyst Report?
Top Page
Oramed Pharm
(NASDAQ:ORMP)
Select Model
Select Model
Rating:59Neutral
Price Target:
$4.50
▲(11.66% Upside)
Action:Reiterated
Date:08/11/26
The score is held back primarily by weak operating performance and ongoing negative operating/free cash flow despite headline net income. Offsetting factors include a strong, low-leverage balance sheet and mildly positive technical setup with a very low P/E, though valuation confidence is limited by cash-flow quality.
Positive Factors
Low-leverage balance sheet
Oramed’s very low leverage and sizable equity base provide durable financial flexibility for a clinical-stage biotech. This conservative capital structure reduces near-term solvency risk, supports continued R&D investment or partnering, and lowers the probability of dilutive emergency financings over the next several months.
Negative Factors
Negative operating and free cash flow
Persistent negative operating and free cash flow indicate Oramed cannot self-fund development from operations. Ongoing cash burn raises structural funding risk, making future R&D progress and milestone achievement contingent on external capital or partner payments over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Low-leverage balance sheet
Oramed’s very low leverage and sizable equity base provide durable financial flexibility for a clinical-stage biotech. This conservative capital structure reduces near-term solvency risk, supports continued R&D investment or partnering, and lowers the probability of dilutive emergency financings over the next several months.
Read all positive factors
Oramed Pharm (ORMP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$186.36M
Dividend YieldN/A
Average Volume (3M)210.74K
Price to Earnings (P/E)1.1
Beta (1Y)0.44
Revenue Growth-100.00%
EPS GrowthN/A
CountryUS
Employees13
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)4.23
Shares Outstanding41,597,355
10 Day Avg. Volume339,860
30 Day Avg. Volume210,739
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.59
Price to Sales (P/S)59.00
P/FCF Ratio-10.65
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.71
Revenue Forecast (FY)N/A
Oramed Pharm Business Overview & Revenue Model
Company Description
Oramed Pharmaceuticals Inc. (ORMP) is a clinical-stage biopharmaceutical company focused on developing oral drug delivery platforms and orally ingestible therapeutics, with a primary emphasis on oral formulations of biologic medicines such as insu...
How the Company Makes Money
Oramed is a clinical-stage biopharmaceutical company; as a result, it generally does not rely on recurring product sales as its primary business model. Instead, it makes (or seeks to make) money primarily through (1) licensing and collaboration ar...
Oramed Pharm Financial Statement Overview
Summary
Income Statement
36
Negative
Balance Sheet
79
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Sep 2023 | Dec 2022 | Aug 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 2.00M | 0.00 | 1.34M | 2.70M | 2.70M |
| Gross Profit | -91.00K | 13.00K | -193.00K | 1.34M | 2.70M | 2.70M |
| EBITDA | 167.27M | 75.44M | -14.87M | 7.32M | -36.98M | -25.04M |
| Net Income | 174.87M | 64.05M | -19.10M | 5.53M | -37.76M | -22.24M |
Balance Sheet | ||||||
| Total Assets | 316.24M | 230.86M | 155.28M | 220.55M | 161.64M | 128.00M |
| Cash, Cash Equivalents and Short-Term Investments | 16.09M | 125.89M | 141.93M | 162.05M | 155.72M | 94.14M |
| Total Debt | 733.00K | 825.00K | 372.00K | 51.62M | 894.00K | 533.00K |
| Total Liabilities | 41.44M | 31.12M | 9.93M | 57.66M | 10.49M | 11.48M |
| Stockholders Equity | 317.47M | 199.74M | 146.26M | 163.82M | 151.81M | 115.77M |
Cash Flow | ||||||
| Free Cash Flow | -5.37M | -11.08M | -8.43M | -10.55M | -29.20M | -21.56M |
| Operating Cash Flow | -5.57M | -9.14M | -8.41M | -10.29M | -28.70M | -21.18M |
| Investing Cash Flow | 21.98M | 5.44M | 105.82M | -73.04M | 30.21M | -22.26M |
| Financing Cash Flow | -16.71M | -4.74M | -52.04M | 51.98M | 11.56M | 101.39M |
Oramed Pharm Technical Analysis
Positive
4.03
Price Trends
4.16
Positive
4.02
Positive
3.49
Positive
Market Momentum
0.06
Negative
60.12
Neutral
70.93
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ORMP, the sentiment is Positive. The current price of 4.03 is below the 20-day moving average (MA) of 4.21, below the 50-day MA of 4.16, and above the 200-day MA of 3.49, indicating a bullish trend. The MACD of 0.06 indicates Negative momentum. The RSI at 60.12 is Neutral, neither overbought nor oversold. The STOCH value of 70.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ORMP.
Oramed Pharm Risk Analysis
Oramed Pharm disclosed 42 risk factors in its most recent earnings report. Oramed Pharm reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Oramed Pharm Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $186.36M | 1.06 | 72.96% | ― | -100.00% | ― | |
56 Neutral | $271.02M | -1.73 | -90.30% | ― | ― | 48.20% | |
52 Neutral | $254.26M | -3.98 | -53.89% | ― | -100.00% | -1813.57% | |
52 Neutral | $34.62M | -0.49 | 681.13% | ― | ― | 43.02% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $151.29M | -1.29 | -123.53% | ― | -100.00% | 52.43% |
* Healthcare Sector Average
ORMP
Oramed Pharm
4.48
2.54
131.05%
WHWK
Whitehawk Therapeutics
4.46
2.85
177.02%
QNCX
Quince Therapeutics
34.04
-299.96
-89.81%
ALXO
ALX Oncology Holdings
1.96
0.99
102.06%
SPRB
Spruce Biosciences
52.64
43.69
488.16%
Oramed Pharm Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Oramed Pharm Updates Bylaws, Streamlining Shareholder Actions
Neutral
Jun 30, 2026
On June 28, 2026, Oramed Pharmaceuticals’ board approved Fifth Amended and Restated Bylaws, effective June 25, 2026, revising procedures for stockholder action by written consent, including record date determination and a 60-day delivery win...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.